Biopharma’s next “win” won’t come from science alone—it’ll come from timing, tender strategy, and a ruthless understanding of how markets behave after patent loss.
If you’re selling to European healthcare systems—whether you’re a commercial vendor, a t…
Biopharma is entering a new kind of “cliff”—not the one investors talk about in earnings calls, but the one that shows up in procurement meetings.
When a blockbuster approaches loss of exclusivity, the market doesn’t just get cheaper. It gets noisier. …
Drugmakers don’t lose to competitors—they lose to the clock.
In patent litigation, timing is everything. But in the quieter, earlier phase—design-around planning—the real risk isn’t just whether a competitor can be sued. It’s whether your team can pr…
Pharma patent strategy is often treated like a filing exercise. It shouldn’t be.
In the pharmaceutical business, patents aren’t just legal instruments—they’re balance-sheet assets, pipeline accelerators, and negotiation leverage. Yet too many companies…
Before You Launch: The Freedom-to-Operate (FTO) Checklist That Can Save Your Company From a $100M Surprise
A launch date is a finish line. But in pharma, it’s also a legal deadline.
The most expensive “oops” in drug development isn’t a failed trial—it’…
Sell the Line—Before the Patent Breaks: A Business Development Playbook for Solid-Dose Equipment Suppliers
The most expensive mistake in pharma equipment sales isn’t pricing. It’s timing.
In solid dose manufacturing, the window between “patent still in…
Sell Before the Cliff: A Business Development Playbook for Sterile Manufacturing Suppliers Targeting Biologic LOE
Biologics don’t just “end.” They cliff. And when Loss of Exclusivity (LOE) hits, the market doesn’t wait for your pipeline to catch up.
Fo…
Patents aren’t just about invention anymore—they’re about timing.
For years, the public conversation around drug pricing has focused on one question: Why do generics take so long to arrive? But the more uncomfortable answer is that, in many cases, th…
GPT, Rosalind, and the Generic Drug Question: What OpenAI’s Life Sciences Model Actually Changes
The most important question in biotech right now isn’t whether AI can “read” biology. It’s whether AI can change the economics of drug development—especial…
GPT-Rosalind and Generic Drugs: What OpenAI’s Life Sciences Model Actually Changes Read Post »
Biopharma teams don’t lose because they lack ambition. They lose because they’re late.
Late to the market. Late to the payer conversation. Late to the competitive intelligence that quietly determines whether your next launch is a triumph—or a scramble….